Share Price:

APNASPENAspen Pharmacare Hldgs133580 (0.00%)

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Annexure 2 – Independent Auditor’s assurance report FY2023, FY2024 and FY 2025

Annexure 3 – Combined Interim Historical Information H1 FY 2026

Annexure 4 – Independent Auditor’s assurance report H1 FY 2026

Annexure 5 – Pro forma financial information

Annexure 6 – Independent Auditor’s assurance Pro forma financial information

Annexure 9 – Independent Auditor’s assurance report(s) on the compilation of the Non-IFRS Financial Information

Paragraph 21 – Advisor consents

Paragraph 11.3 – Summaries of executive director’s employment contracts and non-executive director’s letters of appointment

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below: